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Context: Reference ranges of thyroid stimulating hormone (TSH) and free thyroxine (FT4) are 
defined by their distribution in apparently healthy populations, (2.5th and 97.5th percentiles) 
irrespective of disease risk and used as cut-offs for defining and clinically managing thyroid 
dysfunction.  
Objective: To provide a proof of concept in defining thyroid function optimal health ranges 
based on cardiovascular disease (CVD) mortality risk. 
Design and Participants: 9,233 participants from the Rotterdam Study (mean age 65.0 years) 
were followed up (median 8.8 years) from baseline to date of death or end of follow-up (2012), 
which ever came first (689 cases of CVD mortality). 
Main Outcomes: We calculated 10-year absolute risks of CVD mortality (defined according to 
SCORE project) using a Fine and Grey competing risk model per percentile of TSH and FT4, 
modelled non-linearly and sex- and age-adjusted.  
Results: Overall, FT4 > 90th percentile was associated with a predicted 10-year CVD mortality 
risk >7.5% (p =0.005). In men, FT4 > 97th percentile was associated with a risk of 10.8% 
(p<0.001). In participants ≥ 65 years, absolute risk estimates were <10.0% below the 30th 
percentile (~14.5 pmol/L or 1.10 ng/dL) and ≥15.0% above the 97th percentile of FT4 (~22 
pmol/L or 1.70 ng/dL).  
Conclusions: We describe absolute 10-year CVD mortality risks according to thyroid function 
(TSH and FT4) and suggest optimal health ranges for thyroid function can be defined according 
to disease risk and are possibly sex and age-dependent. These results need to be replicated with 
sufficient samples and representative populations. 
We describe absolute 10-year CVD-mortality risks according to thyroid function and suggest optimal 
health ranges can be defined according to disease risk and are possibly sex and age-dependent. 
1. Introduction 
Reference ranges of blood and other clinical tests are predominantly statistically defined using 
the 2.5th and 97.5th percentile interval of the population distribution in an apparently healthy 
population. These reference ranges are typically established under the assumption of a normal 
distribution or a log-normal distribution and are therefore also referred to as “normal ranges”. 
This definition of a reference range does not account for whether individuals are symptomatic or 
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at risk of potential adverse events or disease. Nevertheless, these biochemically defined reference 
values are frequently used to define sickness and health in clinical practice ignoring the inherent 
risk of the population.   
The reference ranges of thyroid function tests, defined by thyroid stimulating hormone (TSH) 
and free thyroxine (FT4), are examples of reference ranges defined by their distribution. TSH 
and FT4 reference ranges are currently used as cut-offs to define subclinical and overt thyroid 
disease, and guide treatment decisions. However, accumulating evidence suggests that 
subclinical thyroid dysfunction, defined by TSH outside of the reference range but FT4 within 
the reference range, is also associated with various clinical adverse outcomes, including coronary 
heart disease (CHD) and cardiovascular mortality, at the extremes.(1,2) Moreover, even 
differences in thyroid function within the defined reference range are associated with differing 
risk of cardiovascular events including atrial fibrillation, stroke, sudden cardiac death and 
cardiovascular mortality.(3-7) Based on the increased risk of CHD in subclinical 
hypothyroidism, current guidelines advocate treatment with levothyroxine above a TSH of 10 
mIU/L, independent of FT4.(8) Extending this concept, the re-evaluation of thyroid function 
ranges could take clinical adverse events into account and thus move from reference ranges 
towards “optimal health ranges” for thyroid function. 
This approach has been successfully applied to management of myocardial infarction, stroke 
and diabetes using cholesterol, blood pressure or glucose measurements.(9) For example, the 
defined range for total cholesterol does not rely on the distribution of total cholesterol in a 
specific population, but rather on the associated 10-year risk of cardiovascular mortality.(9) 
Pursuing the same strategy for thyroid function might not be as straightforward as for other 
biomarkers. The risk of adverse events is relevant for both high and low thyroid function, 
suggesting a non-linear association, in contrast to cholesterol for example, where the focus is on 
the high end of the measurement. Furthermore, thyroid dysfunction is not solely associated with 
cardiovascular disease (CVD), but has important implications for bone health and possibly also 
cognitive health. (10-13) 
We therefore aimed to calculate the 10-year absolute risk of cardiovascular mortality in a 
large population-based cohort study by the two most commonly used parameters of thyroid 
function, TSH and FT4. We further aimed to define optimal health ranges based on provided 
absolute risk estimates in the whole cohort as well as by sex and age groups.  
2. Subjects and Methods 
A. The Rotterdam Study 
The Rotterdam Study is a prospective population-based cohort study that investigates 
determinants and occurrence of age-related diseases in a middle-aged and elderly population in 
Rotterdam, the Netherlands. The aims and design of the Rotterdam Study have been described in 
detail elsewhere.(14) The Rotterdam Study consists of three independent cohorts: RS Cohort 1 
(RSI), including 7,983 participants aged ≥55 (baseline 1990-1993), RS Cohort II (RSII), 
including 3,011 participants aged ≥55 (baseline 2000-2001) and RS Cohort 3 (RSIII), including 
3,932 participants aged ≥45 (baseline 2006-2008). The Rotterdam Study has been approved by 
the medical ethics committee according to the Population Screening Act: Rotterdam Study, 
executed by the Ministry of Health, Welfare and Sports of the Netherlands.  
B. Study population 
We selected data from participants from the third visit of the first cohort (1997-1999, n=4797) 
and the first visits of the second (2000-2001, n=3011) and third cohort (2006-2008, n=3932), if 
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TSH or FT4 measurements were performed and participants were not using thyroid function 
altering medication, including levothyroxine, anti-thyroid drugs, amiodarone or corticosteroids. 
We did not use the first visit of the first cohort as thyroid function was measured with a different 
assay. All participants in the present analysis provided written informed consent to participate 
and to obtain information from their treating physician. All study participants were followed up 
from the day of baseline laboratory testing to date of death or end of follow-up January 1, 2012 
which ever came first. 
C. Assessment of thyroid function and other baseline measurements 
TSH and FT4 measurements were performed using the same methods and assay in blood 
samples collected between 1997 and 2008, depending on the cohort and stored at -80°C 
(electrochemiluminescence immunoassay for free thyroxine and thyrotropin, “ECLIA”, Roche). 
Body mass index was calculated as body mass (kg) divided by the square of the body height (m). 
Serum cholesterol was measured using standard laboratory techniques. Systolic blood pressure 
was calculated as the average of two consecutive measurements. Over 95% of participants were 
in fasting state when blood was drawn (morning) at the Rotterdam Study center visit. 
Information on tobacco smoking was derived from baseline questionnaires. nformation on 
medication use was obtained from questionnaires in combination with pharmacy records.  
D. Outcome definition 
As primary outcome of interest we selected CVD since it is a leading burden of disease, 
morbidity and mortality.(15) Additionally, the association of subclinical and overt thyroid 
dysfunction with CVD mortality are well-established.(1) Secondary outcomes of interest were 
CHD and stroke (fatal and non-fatal). Methods for collection of data and outcome definitions 
have been previously described .(14,16,17) Information on the vital status of all participants was 
obtained on a weekly basis from the central registry of the municipality in Rotterdam and 
through digital linkage with records from GPs working in the study area. The cause of death was 
established by abstracting information from the medical records of the general practitioners or 
nursing home physicians and hospital discharge letters. Cardiovascular mortality was defined as 
according to the SCORE project definition of fatal CVD including the ICD-10 codes I10-25, I44-
51, I61-73, and R96.(9,18) To test the robustness of our findings we repeated the absolute risk 
estimate calculations using the CVD mortality defined according to previously published 
definition of the Rotterdam Study, which also included non-atherosclerotic cardiovascular 
mortality.(16) CHD was defined as myocardial infarction, cardiac revascularization procedure or 
CHD mortality. Stroke was defined according to World Health Organization (WHO) criteria as a 
syndrome of rapidly developing clinical signs of focal (or global) disturbance of cerebral 
function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause 
other than of vascular origin, including ischemic or hemorrhagic strokes. Outcomes were 
adjudicated by a committee who were blinded to lab results. 
Statistical analyses 
Absolute values of TSH and especially FT4 are assay dependent, but the different immunoassays 
of TSH or FT4 correlate well in non-pregnant adult populations(19,20), as previously also shown 
in the Rotterdam Study.(21) Therefore, to enhance generalizability of our results, we analyzed 
the association of TSH or FT4 in percentiles with the outcomes defined below. Absolute 10-year 
risk estimates of CVD mortality used the percentiles of TSH and FT4 and were calculated 
according to the Fine and Gray model, taking the competing risk of non-CVD deaths into 
account and were adjusted for age and sex.(22) The competing risk for the CHD and stroke 
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analyses were non-CHD and non-stroke deaths respectively. In addition, we performed 
predefined analyses stratifying for age categories and gender. We performed sensitivity analyses 
using a Rotterdam Study based definition for CVD mortality(16), additionally adjusting the TSH 
analyses for FT4 and vice versa as well as additionally adjusting the analyses for cardiovascular 
risk factors used in the SCORE project charts (i.e. smoking, systolic blood pressure, and 
cholesterol).(9) We used the following cut-offs for the risk estimates and color denomination of 
risk categories, which were slightly adjusted from the SCORE project due to the higher average 
age in our population: low risk (< 2.0%, white), low-intermediate risk (2.0-5.0%, light grey), 
intermediate risk (5.0-7.5%, grey), high-intermediate risk (7.5-10.0%, dark grey) and high risk (≥ 
10.0%, black). 
For the CHD analyses we excluded all those with prevalent or missing information on CHD 
at baseline (n=685). For the stroke analyses we excluded all participants with missing 
information at baseline or a history of stroke (n=319). We performed a goodness-of-fit test for 
the Fine and Gray model for the absolute risk estimations, using the Zou Laird Fine test, and this 
revealed no linear, quadratic or log time varying effects of TSH or FT4 (p-value > 0.1 for all 
analyses). Linearity of absolute risk estimates was tested with restricted cubic splines with 3 
knots at the 10th, 50th and 90th percentile. Analyses were performed in R (survival, rms, crrSC 
and cmprsk packages R-project, Institute for Statistics and Mathematics, R Core Team (2013), 
Vienna, Austria, version 3.0.2). 
3. Results 
We included a total of 9,233 participants with a mean age of 65.0 (standard deviation 9.8) years 
of which 55.9% were female (Table 1). During an average follow-up of 8.8 years, with a total of 
75,981 person-years, 2166 deaths occurred of which 689 were CVD deaths according to the 
SCORE criteria and 692 according to the Rotterdam Study criteria. There were 642 CHD events 
and 553 stroke events during follow-up. Completeness of follow-up was 99.6%.(23) 
Absolute risk estimates cardiovascular mortality 
Ten-year absolute risk estimates for CVD mortality across the range of TSH and FT4 are plotted 
in Figure 1. CVD mortality increased with higher FT4 levels (p-value 0.005) and lower TSH 
levels, although not statistically significantly for the latter. The best fit for both TSH and FT4 
analyses was non-linear (p for non-linearity < 0.001, Figure 1). Table 2 shows the different 
percentile cut-offs of TSH and FT4 values with the predicted absolute 10-year risk estimates, 
based on the non-linear association. Overall, FT4 values above the 97th percentile (absolute level 
of approximately 22 pmol/L or 1.7 ng/dL) were associated with a predicted 10-year risk of 9.6% 
(p-value = 0.005). FT4 levels above the 90th percentile corresponded to an increased risk of 7.5% 
and higher for CVD mortality (absolute level of approximately 19 pmol/L or 1.5 ng/dL). 
Sensitivity analyses additionally adjusting for cardiovascular risk factors, using the RS definition 
of CVD mortality or adjusting the TSH analyses for FT4 and vice versa did not change the 
definition of the cut-offs meaningfully (Supplemental Table 1). TSH levels were inversely 
associated with CVD mortality but not statistically significant (Table 1). 
 For men, a risk of ≥10.0% occurred at the 97th percentile of FT4 (p-value < 0.001) and a risk 
of ≥7.5% already occurred at the 60th percentile (Table 3). In women, there was no association 
of the thyroid function markers and risk of CVD mortality (Table 3). In participants younger 
than 65 years of age, the risk of CVD mortality increased with decreasing TSH levels (p-value = 
0.009) with a risk of ≥ 2.0 % from the 30th percentile and lower (~1.40 mIU/L), while FT4 levels 
were not association with CVD mortality (Table 4). In participants older than 65 years of age 
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(Table 4), the absolute risk estimates were <10.0% below the 30th percentile and ≥ 15.0% higher 
than the 97th percentile of FT4. 
Absolute risk estimates CHD and stroke 
Supplemental Figure1 plots the absolute risk estimates of CHD and stroke against the 
continuous FT4 and TSH levels. In the Fine and Grey models, the association of TSH or FT4 
with CHD events was not statistically significant (p-value > 0.5). Higher FT4 levels were 
associated with an increased risk of stroke (p-value = 0.009). TSH levels were inversely 
associated with the risk of stroke, but this did not reach statistical significance. The best fit for 
the CHD analyses was linear, while the best fit for the stroke analyses was non-linear (p for non-
linearity <0.001, Supplemental Figure 1).  
4. Discussion 
This is the first study to propose reference ranges of TSH and FT4 to be based upon the disease 
risk (i.e. absolute risk estimates of CVD) as a proof of concept. Based on our findings, the 
proposed upper limit for FT4 could be the 90th percentile, independent of TSH levels. The 
optimal health ranges for thyroid function based on cardiovascular disease seem to differ 
between men and women and the associations were not statistically significant in women. In 
participants older than 65 years of age, the absolute risk estimates of CVD were <10.0% below 
the 30th percentile (~14.5 pmol/L or 1.1 ng/dL) and ≥ 15.0% higher than the 97th percentile of 
FT4 (~22 pmol/L or 1.7 ng/dL). The associations of TSH and FT4 with CVD mortality were 
non-linear. The association of thyroid function with stroke followed a similar pattern, but the 
association with CHD showed a linear association. 
Reference ranges for the thyroid function biomarkers TSH and FT4 have been derived 
mainly statistically from the 2.5th and 97.5th percentile, similar to reference ranges of other 
laboratory results and clinical tests.(24-26) Subclinical and overt thyroid disease are 
subsequently defined by these biochemical and statistical reference ranges which, in general, do 
not take future health and disease risks into account. However, some guidelines do uphold 
additional cutoffs for treatment based on studies showing an increased risk of cardiovascular 
disease at certain levels.(8,27) For example, the European Thyroid Association guidelines on 
subclinical hypothyroidism (8), make a distinct separation between TSH levels below and above 
10 mIU/L for consideration of levothyroxine treatment. These recommendations are based on a 
study by the Thyroid Studies Collaboration that provided evidence for a higher relative risk of 
CHD with TSH levels higher than 10 mIU/L.(1) However, to our knowledge, there are no studies 
specifically addressing the optimal health ranges based on absolute risk estimates of adverse 
health outcomes.  
Overall, our study shows an absolute 10-year risk of 7.5% or higher with FT4 levels above 
the 90th percentile, corresponding to a cut-off level of FT4 approximately 19 pmol/L (~1.5 
ng/dL). This is however, as expected, different in participants younger than 65 years of age 
compared to those older than 65 years. Also, there seems to be a differential association of 
thyroid function with absolute risk of CVD when comparing men to women. This can, at least 
partially, be attributed to the difference in background absolute risk between the two sexes, 
where, also in our study, women have an inherent lower risk of CVD. However, aside from 
background risk of CVD, there also seems to be a thyroid dependent differential risk when 
comparing men to women, which could be explained by e.g. a difference in set point between the 
sexes (28). Our findings need to be confirmed and validated across different populations, but 
could suggest a sex-specific reference range ought to be considered. These findings need to be 
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confirmed and validated across different populations, but could suggest a sex-specific reference 
range is needed. 
In our study, higher FT4 levels are associated with an increased risk of CVD mortality 
whereas TSH levels showed an expected opposite relation with CVD mortality which did not 
reach statistical significance. The current study is not the first to report an association of FT4 
with clinical events, while the association is lower or absent with TSH.(3,6,21) Based on the log-
linear relationship between TSH and FT4, TSH is perceived as the most sensitive marker in 
subjects with thyroid disease. The lack of association with TSH is therefore remarkable. One 
explanation could be that in euthyroid subjects, TSH predominantly reflects the pituitary-thyroid 
axis set point rather than disease risk,(29) while, independent of TSH, circulating FT4 (and 
subsequently FT3 acting intracellular) represents the bioavailable thyroid hormone that can be 
taken up by cells, thereby leading to clinical consequences of thyroid hormones peripherally.  
Cholesterol is a modifiable risk factor for CVD mortality and diagnosis and treatment targets 
for cholesterol are included within optimal primary and secondary prevention of CVD mortality. 
In our study, we show that FT4 is also a potentially modifiable risk factor for CVD and CVD 
mortality, especially in men and the elderly. For cholesterol, the average risk difference, as 
derived from the SCORE risk chart for low risk countries (9), when comparing 65 year old men 
with a cholesterol level of 7 mmol/L to 65 year-old men with a cholesterol level of 4 mmol/L is 
approximately 4.0%. This is similar to the risk difference when comparing men with an average 
age of 65 years in the highest 10th percentile of FT4 (cut-off ~ 1.5 ng/dL) to those in lowest 10th 
percentile (cut-off ~ 1.0 ng/dL), namely 4.3%. Whether modifying higher FT4 levels with anti-
thyroid drugs will indeed result in this cardiovascular mortality risk reduction still needs to be 
determined. 
There are several strengths to our study including the population-based design, the large size 
of the study population, the completeness of follow-up and the fact that outcomes were defined 
independently from baseline thyroid function. Nevertheless, the currently proposed optimal 
health ranges should be interpreted with caution. First of all, even though CVD is one of the 
most important clinical outcomes, the presented absolute risk estimates are solely based on 
cardiovascular mortality and our findings as such should be considered as a proof of concept. 
Furthermore, The Netherlands is classified as a low cardiovascular mortality risk country by the 
European Society of Cardiology and therefore estimates are not generalizable to countries with 
higher CVD mortality risk.(30) The Rotterdam Study consists of participants of 45 years and 
older and mainly Caucasians with, on average, a sufficient iodine status.(31,32) Also, only one 
baseline measurement of thyroid function was available, which holds true for most population-
based cohort studies. The intra-individual set-point is much tighter than the inter-individual set-
point, meaning that within an individual the changes in time are much smaller than between 
individuals (33). Nevertheless, we could not investigate how changes in thyroid function could 
affect CVD risk and whether repeated measurements of thyroid function could better 
differentiate risk among cohort participants. The absolute levels of TSH and especially FT4 
depend on the assay used and are therefore variable. Immunoassays for FT4 are affected by 
changes in serum binding proteins that occur in disease and pregnancy (34). We therefore used 
the percentiles of the measurements to study the associations and define the optimal health 
ranges, because of the strong correlation between the different assays of TSH or FT4 in 
community-dwelling non-pregnant populations. These results are therefore potentially more 
generalizable to other populations. This is also the reason to advice that the calculation of these 
percentiles is country, iodine status, region and if possible even laboratory specific. 
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The mentioned limitations of our study also highlight the need for further research. Therefore 
our approach to define thyroid function adequacy focused on cardiovascular mortality need to be 
confirmed in similar populations but also replicated in complementary populations such as 
younger participants, other ethnicities and in regions with different current and historical iodine 
status.(35) Cardiovascular disease is an established and well-studied outcome in relation to 
thyroid function. However, recently, there is increasing interest in the association of thyroid 
function with other outcomes as well, such as cognition. Therefore, importantly, consensus is 
needed on which clinical outcomes are or could be relevant in defining the optimal health ranges 
for thyroid function, beyond cardiovascular disease. Lastly, and beyond the discussion on thyroid 
function optimal health ranges, consensus is also needed on which cardiovascular risk is 
considered too high and whether this is similar for all populations. For example, a 10-year 
absolute risk of 2.5% for CVD mortality for a person of 45 years of age might not be deemed 
equally acceptable compared to the same risk in a person of 75 years. 
This is a population-based study, and therefore risks and benefits of treatment decisions were 
not explored. While randomized controlled trials are the best evidence for defining treatment cut-
offs, they are costly and not always able to address the timeliest issues. In the absence of results 
from such trials in the near future, defining the optimal health ranges by determining the absolute 
risk estimates of disease, in various observational studies from representative populations, is 
perhaps the most feasible.  
In summary, we propose an approach to define thyroid function based not only on 
population’s distribution but taking into account health and disease risk. We describe the 
absolute 10-year risk of cardiovascular mortality associated with TSH and FT4 and provide an 
example of defining optimal health ranges based on cardiovascular mortality risk using data from 
a large population-based study. Further research is needed to investigate optimal health ranges 
based on thyroid-relevant clinical outcomes in sufficiently powered studies with representative 
samples from multiple populations.  
5. Appendix 
Supplemental Table 1 
Supplemental Figure 1 
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Figure 1. Absolute 10-year risk of CVD mortality by TSH and FT4. Absolute 10-years risks of 
CVD mortality were calculated taking competing risk of death by other causes into account, and 
are plotted against TSH and FT4 percentiles and absolute values, with 95% confidence intervals. 
P for non-linearity < 0.001 for both TSH and FT4 analyses. Abbreviations:  CVD cardiovascular 
disease FT4 free thyroxine, TSH thyroid-stimulating hormone. 
Table 1: Baseline characteristics of included participants in the Rotterdam Study with TSH or 
FT4 measurements and no thyroid function altering medication 
Variable Mean (SD)a 
Number of participants 9233 
Age, years 65.0 (9.8) 
Female, N (%) 5157 (55.9) 
History of diabetes, N (%) 1097 (11.9) 
BMI kg/m2 27.2 (4.2) 
Cholesterol mmol/L 5.7 (1.0) 
Smoking, N (%)  
   current 1975 (21.4) 
   past 4380 (47.4) 
   never 2878 (31.2) 
Systolic BP, mmHg 139.5 (21.0) 
TSH ImU/L median (IQR) 1.90 (1.29-2.74) 
FT4 pmol/L 15.6 (2.2) 
FT4 ng/dL 1.21 (0.2) 
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a Values are means and SD unless otherwise specified 
Abbreviations: BMI = body-mass index; BP = blood pressure; FT4 = free thyroxine; IQR = inter-quartile range; N= 
number; SD = standard deviation; TSH = thyroid-stimulating hormone 
Table 2: Absolute 10-year risk estimates for CVD mortality according to percentiles of TSH and 
FT4 (n= 9227)* 
Predicted 10-year absolute risk of event (n= 689 cases) 
TSH, 
percenti
le  
<2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-
50th 
50-
60th 
60-70th 70-
80th 
80-
90th 
90-
95th 
95-
97th 
>97th P-
trend   
Absolut
e risk 
estimat
es 
8.3
% 
8.3
% 7.4% 6.9% 6.5% 5.9% 6.0% 5.5% 5.5% 
5.4
% 5.3% 
6.0
% 5.5% 6.0% 0.59 
N 149 164 471 944 959 952 930 958 944 953 933 444 257 169  
Mean 
TSH 0.03 0.19 0.53 0.97 1.26 1.52 1.76 2.04 2.36 2.77 3.45 4.54 5.74 13.53  
FT4 
percenti
les 
<2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-
50th 
50-
60th 
60-70th 70-
80th 
80-
90th 
90-
95th 
95-
97th 
>97th P-
trend 
Absolut
e risk 
estimat
es 
4.5
% 
4.4
% 5.1% 4.7% 4.7% 5.2% 5.8% 6.0% 6.2% 
6.9
% 7.5% 
8.4
% 8.9% 9.6% 0.005 
N 185 190 476 941 952 961 940 953 939 947 911 463 238 131  
Mean 
FT4 
pmol/L 
8.93 11.57 12.57 13.46 14.16 14.73 15.27 15.80 16.36 
17.0
1 17.83 
18.8
5 19.82 22.01  
Mean 
FT4 
ng/dL 
0.69 0.90 1.00 1.05 1.10 1.14 1.19 1.23 1.27 1.32 1.39 1.46 1.54 1.71  
Models are adjusted for age and sex and computed using a competing risk model.  Risk legend: low risk (< 2.0% , 
white), low-intermediate risk (2.0-5.0%, light grey), intermediate (5.0-7.5%, grey), high-intermediate risk (7.5-
10.0%, dark grey), high risk (≥ 10.0%, black). 
Abbreviations: CVD = cardiovascular disease; FT4 = free thyroxine; N = number; TSH = thyroid stimulating 
hormone 
* 6 people excluded due to missing cause of death 
Table 3: Absolute 10-year risk estimates for CVD mortality according to percentiles of TSH and 
FT4 (n= 9227)* 
Predicted 10-year absolute risk of event (n= 689) 
Men, N= 4072 
cases = 357 
              
TSH, 
percentile  
<2nd 2-5th 5-10th 10-
20th 
20-
30th 
30-
40th 
40-50th 50-
60th 
60-
70th 
70-
80th 
80-
90th 
90-
95th 
95-97th >97th P-
trend 
Absolute 
risk 
estimates 
11.4
% 8.6% 8.8% 8.0% 
7.1
% 7.0% 7.3% 6.4% 
6.6
% 6.4% 
6.4
% 7.8% 7.2% 7.1% 0.46 
N 44 78 216 461 461 472 452 450 408 418 354 159 60 39  
FT4 
percentile
s 
<2nd 2-5th 5-10th 10-
20th 
20-
30th 
30-
40th 
40-50th 50-
60th 
60-
70th 
70-
80th 
80-
90th 
90-
95th 
95-97th >97th P-
trend 
Absolute 
risk 
estimates 
4.4% 5.3% 6.1% 5.4% 5.5% 6.1% 6.8% 7.5% 
7.6
% 8.3% 
8.4
% 9.0% 9.0% 10.8% <0.001 
N 62 51 199 377 352 412 393 450 425 461 458 244 128 60  
Women, N = 
5155, cases = 332 
              
TSH, 
percentile  
<2nd 2-5th 5-10th 10-
20th 
20-
30th 
30-
40th 
40-50th 50-
60th 
60-
70th 
70-
80th 
80-
90th 
90-
95th 
95-97th >97th P-
trend 
Absolute 7.0% 8.1% 6.3% 5.9% 5.9 4.7% 4.6% 4.7% 4.6 4.5% 4.6 5.0% 5.1% 5.9% 0.99 
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risk 
estimates 
% % % 
N 105 86 255 483 498 480 478 508 536 535 579 285 197 130  
FT4 
percentile
s 
<2nd 2-5th 5-10th 10-
20th 
20-
30th 
30-
40th 
40-50th 50-
60th 
60-
70th 
70-
80th 
80-
90th 
90-
95th 
95-97th >97th P-
trend 
Absolute 
risk 
estimates 
4.8% 4.3% 4.2% 4.2% 4.3% 4.5% 5.0% 4.7% 
5.1
% 5.6% 
6.7
% 7.8% 8.8% 8.6% 0.27 
N 123 139 277 564 600 549 547 503 514 486 453 219 110 71  
Models are adjusted for age and sex and computed using a competing risk model.  Risk legend: low risk (< 2.0% , 
white), low-intermediate risk (2.0-5.0%, light grey), intermediate (5.0-7.5%, grey), high-intermediate risk (7.5-
10.0%, dark grey), high risk (≥ 10.0%, black) 
Abbreviations: CVD = cardiovascular disease; FT4 = free thyroxine; N = number; TSH = thyroid stimulating 
hormone 
* 6 people excluded due to missing cause of death 
Table 4: Absolute 10-year risk estimates for CVD mortality according to percentiles of TSH and 
FT4 (n= 9227)* 
Predicted 10-year absolute risk of event (n= 689) 
Age < 65 years, 
N= 5172 cases = 
82 
              
TSH, 
percentile  
<2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-
70t
h
 
70-
80th 
80-
90th 
90-
95th 
95-
97th 
>97th P-
trend   
Absolute 
risk 
estimates 
2.6% 3.0% 2.6% 2.4% 2.2% 1.9% 1.7% 1.4% 1.3% 
1.2
% 
1.0
% 
0.9
% 
0.8
% 0.9% 0.009 
N 56 59 234 490 523 557 532 573 564 580 554 233 134 83  
FT4 
percentile
s 
<2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-
70t
h
 
70-
80th 
80-
90th 
90-
95th 
95-
97th 
>97th P-
trend  
Absolute 
risk 
estimates 
1.2% 1.1% 1.3% 1.3% 1.3% 1.5% 1.5% 1.8% 1.8% 
1.9
% 
2.1
% 
2.2
% 
2.4
% 2.4% 0.20 
N  96 97 285 565 556 561 516 526 508 535 512 239 115 61  
Age ≥ 65 years, N 
= 4055, cases = 
607 
              
TSH, 
percentil
e  
<2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-
70t
h
 
70-
80th 
80-
90th 
90-
95th 
95-
97th 
>97th P-
trend 
Absolute 
risk 
estimates 
11.8
% 11.5% 
12.2
% 11.9% 11.5% 11.3% 11.2% 11.1% 
11.
1% 
11.2
% 
10.
9% 
11.
4% 
10.
5% 
10.8
% 0.76 
N 93 105 237 454 436 395 398 385 380 373 379 211 123 86  
FT4 
percentil
es 
<2nd 2-5th 5-10th 10-20th 20-30th 30-40th 40-50th 50-60th 60-
70t
h
 
70-
80th 
80-
90th 
90-
95th 
95-
97th 
>97th P-
trend 
Absolute 
risk 
estimates 
8.1% 7.9% 10.2% 9.3% 9.2% 10.2% 10.7% 11.1% 
11.
4% 
13.1
% 
14.
1% 
14.
7% 
14.
9% 
15.7
% 0.005 
N  89 93 191 376 396 400 424 427 431 412 399 224 123 70  
Models are adjusted for age and sex and computed using a competing risk model.  Risk legend: low risk (< 2.0% , 
white), low-intermediate risk (2.0-5.0%, light grey), intermediate (5.0-7.5%, grey), high-intermediate risk (7.5-
10.0%, dark grey), high risk (≥ 10.0%, black) 
Abbreviations: CVD = cardiovascular disease; FT4 = free thyroxine; N = number; TSH = thyroid stimulating 
hormone 
* 6 people excluded due to missing cause of death 
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